Capecitabine, an oral prodrug of 5-fluorouracil, is a novel antineoplastic agent used in the treatment of metastatic colon and breast cancers. A seriesof dermatologic reactions associated with oral capecitabine have been reported, including "dermatitis," leopardlike vitiligo, "erythematous rash," onycholysis,palmar-plantar erythrodysesthesia, photoeruption, pyogenic granulomas, radiation recall, and xerosis.1,2 Toour knowledge, we report the first case of inflammation of actinic keratosesas a result of systemic treatment with oral capecitabine.
Lewis KG, Lewis MD, Robinson-Bostom L, Pan TD. Inflammation of Actinic Keratoses During Capecitabine Therapy. Arch Dermatol. 2004;140(3):367–368. doi:10.1001/archderm.140.3.367
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: